A comparative analysis of select P450 enzymes in uninduced and PB/BNF-induced hamster and rat liver S9

Kristie Evans1, Slaydon Boitnotte1, Errol Zeiger2

  • 1Molecular Toxicology, Inc., 157 Industrial Park Drive, Boone, NC 28607, USA.

Insights

Assessing drug impurities like N-nitrosamines requires reliable mutagenicity tests. Hamster liver S9 shows higher metabolic activity than rat liver S9 for N-nitrosamine bioactivation, making it preferable for in vitro testing.

Area of Science:

  • Pharmaceutical Science
  • Toxicology
  • Drug Safety

Background:

  • Ensuring drug safety necessitates evaluating potentially carcinogenic N-nitrosamine impurities.
  • The in vitro Ames test, using rodent liver S9 fractions, is standard for assessing mutagenicity but shows inconsistencies with N-nitrosamines.
  • Concerns exist regarding the liver S9's capacity to activate N-nitrosamines into their mutagenic forms.

Purpose of the Study:

  • To comparatively assess the metabolic competence of rat and hamster liver S9 fractions for N-nitrosamine bioactivation.
  • To evaluate the activity of cytochrome P450 (CYP) enzymes involved in N-nitrosamine metabolism in different rodent S9 preparations.

Main Methods:

  • Utilized Vivid® CYP450 Screening Kits and the 7-benzyloxyquinoline assay to measure P450 enzyme activities.
  • Assessed both uninduced and induced rat and hamster liver S9 preparations.
  • Quantified substrate activities relevant to N-nitrosamine metabolism.

Main Results:

  • Hamster liver S9 consistently exhibited higher CYP activity than rat liver S9 under identical conditions.
  • Induced rat S9 showed significant increases in 7-benzyloxyquinoline conversion (CYP3A-like activity) (15.7-fold).
  • Induced hamster S9 demonstrated a substantial increase in CYP2A6-like activity, which was approximately 60-fold higher than in induced rat S9.

Conclusions:

  • Both rat and hamster liver S9 fractions possess relevant P450 enzyme activities for N-nitrosamine bioactivation.
  • Hamster liver S9 is recommended for in vitro N-nitrosamine testing due to its superior overall P450 activity levels.
  • These findings aid in selecting appropriate systems for accurate N-nitrosamine mutagenicity assessments.

Related Concept Videos

Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...